Century Therapeutics (IPSC) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Sutro Biopharma (STRO) over the past year, gaining 129.0% versus a gain of 74.5%. Over five years, STRO leads with a -92.3% price change compared with -93.4% for IPSC. Sutro Biopharma is the larger company by market cap ($251.9 million vs $228.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | STRO |
|---|---|---|
| Share price | $1.26 | $15.19 |
| Market cap | $228.15M | $251.87M |
| 1-day change | -1.56% | +3.62% |
| YTD return | +28.64% | +26.71% |
| 1-year return | +128.98% | +74.52% |
| 5-year return | -93.37% | -92.28% |
| EPS (TTM) | $-0.93 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $43.85 |
| 52-week low | $0.435 | $7.15 |
| Distance from 52-week high | -58.55% | -65.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +276.98% | +210.93% |
| Average volume | 649.61K | 286.74K |
| Shares outstanding | 181.08M | 16.58M |
| Employees | 78 | 128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed STRO by 54.5 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 128 employees
IPSC vs STRO FAQ
Which is bigger, Century Therapeutics or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $251.87M compared with $228.15M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, IPSC or STRO?
IPSC returned +128.98% over the past 12 months, compared with +74.52% for STRO (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.